NEW YORK (GenomeWeb News) – The drug developer Abbott has tapped Oncomethylome to profile tumors for its cancer drug research efforts, Oncomethylome said today.
Oncomethylome will use its high-throughput DNA methylation platform to test its biomarkers on biological samples provided by Abbot, the company said.
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.